Aligos Therapeutics (ALGS) FCF Margin (2021 - 2026)
Aligos Therapeutics' (ALGS) quarterly FCF Margin came in at 817.24% in Q1 2026, up 590591.0% YoY from N/an in Q1 2025, and up 93.65% on a QoQ basis from 12866.86% in Q4 2025.
Aligos Therapeutics (ALGS) FCF Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 6 years of FCF Margin data on file, last reported at 817.24% in Q1 2026.
- Quarterly FCF Margin rose 590591.0% year-over-year to 817.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2137.29% (down 16316994.0% YoY) and the FY2025 annual result came in at 3774.15%, up 2043932.0% from the prior year.
- FCF Margin rose to 817.24% in Q1 2026, from 12866.86% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1991.04% in Q4 2023 to a low of 15995.71% in Q1 2023.
- A 5-year average of 3039.83% and a median of 1606.63% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 1518090 bps — and 2024, when it jumped 1271819 bps.
- Tracing ALGS's FCF Margin over 5 years: stood at 121.33% in 2022, then surged by 1741 bps to 1991.04% in 2023, then tumbled by 65 bps to 688.99% in 2024, then plunged by 1967 bps to 12866.86% in 2025, then surged by 94 bps to 817.24% in 2026.
- The last three FCF Margin figures came in at 817.24% (Q1 2026), 12866.86% (Q4 2025), and 1606.63% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -817.24% |
| Dec 31, 2025 | -12,866.86% |
| Jun 30, 2025 | -1,606.63% |
| Mar 31, 2025 | -6,723.15% |
| Dec 31, 2024 | 688.99% |
| Sep 30, 2024 | -1,608.08% |
| Jun 30, 2024 | -1,837.23% |
| Mar 31, 2024 | -3,277.52% |
| Dec 31, 2023 | 1,991.04% |
| Sep 30, 2023 | -1,874.29% |
| Jun 30, 2023 | -317.09% |
| Mar 31, 2023 | -15,995.71% |
| Dec 31, 2022 | -121.33% |
| Sep 30, 2022 | -417.44% |
| Mar 31, 2022 | -814.82% |
| Dec 31, 2021 | -10,065.12% |
| Sep 30, 2021 | -1,656.80% |
| Jun 30, 2021 | -1,499.68% |
| Mar 31, 2021 | -3,308.02% |